Will the WTO Waiver of Intellectual Property Rights Help or Harm the COVID Response ?

By Stefanie Offe

On Wednesday, June 8th, SME Europe of the EPP together with the Property Rights Alliance organised the webinar entitled „Will the WTO Waiver of Intellectual Property Rights help or harm the COVID Response?” to discuss the impact of the WTO TRIPS Waiver on IP Rights to keep ensuring that manufacturers still have an incentive to innovate, ensure the safety and efficacy of medicines and have the resources to invest in the next generation of cures.

Hosted by Jörgen Warbron MEP, INTA & TRAN Committee and Vice-President of SME Europe of the EPP, and moderated by Philip Thompson, Policy Analyst for IP and Trade at Property Rights Alliance and Author of the “Trade barriers index”, the webinar saw the participation of Horst Heitz, Executive Director of SME Europe of the EPP; The Lord James Bethell of Romford, Parliamentary Under-Secretary of State at the Department of Health and Social Care of the UK Government; John O’ Connell, Executive Director of the Taxpayers’ Alliance; Matthew Lesh, Head of Public Policy at the Institute for Economic Affairs; and Prof. Cesare Galli, Founding & Managing Partner of IP Law Galli and Chair of Intellectual Property Law at the University of Parma.

The Lord James Bethell of Romford remarked that the idea of waiving the IP rights is completely wrong. “Any efforts to undermine financial arrangements around that system would be counterproductive for both the developed world and also to the economic South.”

Jörgen Warborn MEP stated the issues of copyrights in his previous work and compared this waiver with a stage offered theft meaning to give away the companies´ research. He stressed the importance to strengthen the IP rights in an economy that is based on knowledge and creativity. “We cannot make the IP rights less worth that would hurt our prosperity at the end of the day.” Furthermore, he suggested a growth summit in Europe to restart the economy, to create more jobs and more growth in which IP issues should have a core of the discussion.

The discussion was supported by Matthew Lesh. He underlined the great COVID vaccine response that happened out of huge investments over many years by researchers, companies and individuals. He additionally added that the TRIPS waiver will undermine the process by investing in clinical trials and research. “The entire waiver makes very little sense given long-term consequences.”

Prof. Cesare Galli agreed with the previous speeches by the panellists and said that without IP rights only the people will win with political protection to trade without responsibility in the event of failure as it is happening in Russia and China. He underlined the importance to create competition between innovators so that the market can offer more choices. “There is no reason to think that through the waiver we will increase the production of vaccines.” Moreover, he underlined that in the view of better protection of the rights, which is also constitutional rights in many European countries, the waiver would not be associated with a shortcut but rather a dead end.

Before the open discussion started, the last opening statement was made by John O´´´ Connell.He stated that basically, the TRIPS waiver tries to solve a problem that doesn’t necessarily exists. It should rather be focused on the issues encountered in supply and manufacturing rather than on the abandonment of intellectual property. Growth, jobs and innovation in the private sector will solve these big problems, not TRIPS waivers to move forward.

The publication of this document received financial support from the European Parliament. Sole liability rests with the author. The European Parliament is not responsible for any use that may be made of the information contained therein.

Privacy Policy
SME Europe

Privacy Policy

Disclaimer

SME Europe of the EPP maintains this website to enhance public access to information about its initiatives. Our goal is to keep this information timely and accurate. If errors are brought to our attention, we will try to correct them. This privacy policy will explain how our initiative uses the personal data we collect from you when you use our website.

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalised web experience.
Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.

You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.
All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance.